Safety of Thiopurine Use in Paediatric Gastrointestinal Disease. E Miele et al. JPGN 2020; 71: 156-62. Useful review of thiopurines for IBD and for autoimmune hepatitis
The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial. M Matar et al. JPGN 2020; 71: 237-42. This study showed that 66 (of 78) who completed 72 weeks of treatment had improved (but not normalized) linear growth (height z-score at baseline improved from -0.62 to -0.33 (P=0.005) and normalization of weight and BMI. The presence of perianal disease was associated with diminished growth velocity. Overall, this study adds to the literature that anti-TNF agents can reverse growth failure associated with Crohn’s disease.
Full text: Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease RC Ungaro et al. Gastroenterol 2020; DOI: https://doi.org/10.1053/j.gastro.2020.03.039 Key finding: When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07–0.31) was significantly associated with a lower risk of major adverse outcome. This study is reinforced by recent data published at DDW 2020 -Abstract 401: N Plevris et al. “Early Mucosal Healing Key to Long-Term Success.” This was highlighted by Miguel Regueiro in Gastroendonews.com. Among 375 patients, those who achieved a fecal calprotectin (FC) <250 mcg/g within one year of diagnosis, the disease progression was 65% slower than those with FC values that did not normalize within a year. Initiation of a biologic within 3 months of diagnosis, more than quadrupled the likelihood of FC normalization within one year.
Pingback: In Case You Missed It: IBD Year in Review (Eric Benchimol) | gutsandgrowth
Pingback: Histologic Healing and IBD Outcomes | gutsandgrowth
Pingback: Microscopic Disease Does Not Predict Relapse in Crohn’s Disease | gutsandgrowth